Elizabeth Stoner was appointed Director of iBio, Inc., effective May 7, 2026. As of November 6, 2026, iBio, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 8, 2026 to August 4, 2026, naming 1 appointment and 1 departure (Form 8-K, May 8, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like iBio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
iBio, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-08 to 2026-08-04. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as iBio, Inc. files it.
Also on the record for iBio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 14, 2026 | Stake report, Schedule 13G, by Coastlands Capital LP | 9.72% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Lynx1 Capital Management LP | 5.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Vestal Point Capital, LP | 7.9% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by EcoR1 Capital, LLC | 4.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Logos Global Management LP | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | — | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 9.99% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 5.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs iBio, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on iBio, Inc. and the records around it.
iBio, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Company profile and every filing Jan 2026
- Form D filing Jan 2026
- Form D filing May 2025
- Who owns it
Companies that share a holder
- Patrick J. Crutcher also filed stake reports on 1 other company: Avalo Therapeutics, Inc. (Aug 2025)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026)
Watch iBio, Inc.
Get an email when iBio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on iBio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on iBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on iBio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 33 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-04 | Reported | not named in the filing | 8-K, 2026-08-04 | ||
| 2026-05-08 | In | Director | 2026-05-07 | 8-K, 2026-05-08 | |
| 2026-05-08 | Out | Director | 8-K, 2026-05-08 |
Who leads iBio, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Evert Schimmelpennink, departure reported (filed 2026-05-08). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on iBio, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch iBio, Inc. (free up to 3)
Find people with the same kind of experience as the Director at iBio, Inc., with the record behind each one.
Find candidates like Director at iBio, Inc.Every change, in the filing's words
Reported
Effective July 31, 2026, Molly Carr, M.D. was appointed as the Chief Medical Officer of iBio, Inc. (the "Company").
- Dr. Molly Carr, M.D., age 59, is a physician executive with extensive experience in the biotechnology and pharmaceutical industries.
- Immediately prior to joining the Company, she served as Clinical Head, Associate Vice President, Insulin and Glucagon Franchise at Eli Lilly and Company ("Eli Lilly") since 2021.
- In that role, she oversaw clinical development activities for Eli Lilly's insulin and glucagon portfolio, including late-stage development programs for efsitora, a once-weekly insulin candidate, as well as other diabetes and metabolic disease therapies.
- Prior to assuming that position, Dr. Carr served as Senior Medical Fellow, Associate Vice President, Diabetes Business Development and External Innovation at Eli Lilly from 2018 to 2021, where she led the evaluation of external business development opportunities and supported licensing and strategic transactions in diabetes and related metabolic diseases.
- Before joining Eli Lilly, Dr. Carr held positions of increasing responsibility at GlaxoSmithKline plc, including Endocrine Scientific Lead, Metabolic Pathways & Cardiovascular R&D Unit, and Global Medical Affairs Lead for albiglutide.
Appointed: Elizabeth Stoner, Director, effective 2026-05-07
On May 7, 2026, the Board of Directors (the "Board") of iBio, Inc. (the "Company"), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026, and to serve until the Company's 2028 annual meeting of stockholders, at which time her term of office shall expire and a Class II director shall be elected for a full term of three years, or until her re-election or earlier resignation or removal.
Departing: Evert Schimmelpennink, Director
On May 7, 2026, Evert Schimmelpennink, a member of the Board, notified the Company of his decision to resign from the Board, including from his position as a member of the Compensation Committee of the Board, effective immediately.
- Dr. Stoner was also appointed to serve as a member of the Compensation Committee of the Board.
- Dr. Stoner, age 75, is currently an Entrepreneur Partner at MPM BioImpact, supporting both private and public funds.
- Dr. Stoner has held several leadership roles at MPM BioImpact portfolio companies including interim Chief Executive Officer of Semma Therapeutics; and founder, Chief Medical Officer and Chief Development Officer of Rhythm Pharmaceuticals, Inc. She also served in clinical and advisory roles at Clinical Ink, Inc., Potenza Therapeutics, Inc., Solasia Pharma, Werewolf Therapeutics Inc., and TriNetX, LLC.
- Prior to joining MPM BioImpact, Dr. Stoner was Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries.
- Prior to joining the Merck Research Laboratories, she was an Assistant Professor of Pediatrics at Cornell University Medical College.
- Dr. Stoner currently serves as a member of the board of two privately held, clinical stage biopharmaceutical companies, LIB Therapeutics, since 2016, and Antiva Bioscience, since 2023.
- She also served as a member of the board of Arovella Therapeutics Ltd., a biotechnology company traded on the Australian Securities Exchange, from November 2021 until February 2026.
Tools for this story
Each opens in a new tab, filled in for iBio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.